Uterine Neoplasms

168 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Uterine Neoplasms
Treatment and conditionWhere it standsTrials
Adaptive Hypofractionated Radiotherapy for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebelimab Combined with Apatinib for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AK105 and anlotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 1 year for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-PD1 agent therapy - 2 years for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Axitinib + AVELUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azenosertib for uterine neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
B1962 for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab + lenvatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
camrelizumab; famitinib malate for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin-Paclitaxel for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib + Daraxonrasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX-19477 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Glucagon-like peptide 1 receptor agonist for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GnRHa + Letrozole for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lorigerlimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mazdutide for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Observation for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Olaparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
paclitaxel combined with platinum for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab + nesuparib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prexasertib + Gemcitabine for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Puxitatug Samrotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rescue medications + Sacituzumab tirumotecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab + cisplatin for uterine neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sacituzumab tirumotecan for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Serplulimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHR-A1811 Injection for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sintilimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sirolimus for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talazoparib + avelumab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topotecan + toripalimab for endometrial neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Trastuzumab deruxtecan for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for endometrial neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for endometrial neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1